OncoSignal
Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:17 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension (0954A-325)

NCT00449111 · Organon and Co · PHASE3 · terminated · last registry update 2024-08-15 · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

No reason was published

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

KindQuoteOur categorySource
StatedThe registry record gives no reason–Registry record, Organon and Co

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against AGTR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

  • Internal portfolio and board discussions
  • Unpublished trial data and interim analyses
  • Terms of any partner or licence decision